Pharma Capital

CytomX Therapeutics shoots higher as it's set for US$200mln upfront payment from Bristol-Myers Squibb

CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.
Cancerous cells
CytomX's shares, which have gained 32% over the past three months, were up 23.7% to US$18.78 in early morning trade

CytomX Therapeutics Inc (NASDAQ:CTMX) saw its shares shoot almost 25% higher in early New York trading after the biotech firm said it would receive a US$200mln upfront payment from drugs giant Bristol-Myers Squibb Co. (NYSE:BMY).

The payment is part of the expansion of a collaboration pact to discover cancer treatments using CytomX's Probody platform.

CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.

Bristol-Myers’ head of discovery, Carl Decicco, said: “CytomX's Probody platform has enhanced our discovery research as we seek to direct the therapeutic effects of immunotherapy in a more targeted approach against tumor.”

CytomX's shares, which have gained 32% over the past three months, were up 23.7% to US$18.78 in early morning trade.



Register here to be notified of future CTMX Company articles
View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.